Abstract
Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies. TCF7L2 rs7903146 C>T and CTRB1/2 rs7202877 T>G minor allele carriers were both associated with a smaller reduction in HbA1c after gliptin treatment when compared with major allele carriers. After replication in further studies, these observations could be of clinical significance in helping to identify patients with potentially lower or higher response to gliptin treatment.
Keywords:
CTRB1/2; GLP-1 receptor agonists; TCF7L2; Type 2 diabetes mellitus; gliptins; incretin effect.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Chymotrypsin / genetics
-
Chymotrypsin / metabolism
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / genetics*
-
Diabetes Mellitus, Type 2 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacokinetics
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Glucagon-Like Peptide-1 Receptor / agonists
-
Humans
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / therapeutic use*
-
Incretins / agonists*
-
KCNQ1 Potassium Channel / genetics
-
KCNQ1 Potassium Channel / metabolism
-
Pharmacogenomic Testing
-
Pharmacogenomic Variants
-
Polymorphism, Single Nucleotide
-
Transcription Factor 7-Like 2 Protein / genetics
-
Transcription Factor 7-Like 2 Protein / metabolism
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Incretins
-
KCNQ1 Potassium Channel
-
KCNQ1 protein, human
-
TCF7L2 protein, human
-
Transcription Factor 7-Like 2 Protein
-
Chymotrypsin
-
chymotrypsin B